From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: NCYT

Search articles by EPIC code

Private Eye on Novacyt - this is damning

I have warned you time and time again that Novacyt (NCYT) was a ramp with the sole purpose of allowing now departed CEO Graham Mullis to trouser an enormous cash bonus based on the share price on just one day. In the end Mullis trousered £8.5 million but, last week, Private Eye served up a great article showing how the company has a cultrure of lying and fabrication and, had investors known the truth about tests that did not work or which were contaminated, Mullis would be far less well off than he is today. This is a scandal and the ramifications could be very serious. Potentially a claim by the DHSC could wipe out most of this  company's balance sheet (cash of £100million) with ongoing cash burn now that sales of its covid tests are evaporating, taking out the rest. This remains a bargepole stock/short.  The article is below. 


Novacyt admits possibly loss making – a reminder of that porcine executive bonus plan

You may remember that directors of Novacyt (NCYT) made an abosolute killing because of a cash bonus plan which was dependent on the share price at October 17 2020. Assisted enormously by news of a massive contract win with the DHSC announced on September 29 the shares were c930p on D day. Today they are 325p as the horror of the DHSC feck up emerges. As a reminder here is what Novacyt said on 29 September sending its shares roofing it:

Page 2 of 5 (47 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments